| | 
| | |  |  | Webcast
Idera Pharmaceuticals, Inc. at Rodman & Renshaw Global Investment Conference (Live)
09/15/10 at 10:50 a.m. ET |
| Webcast
Idera Pharmaceuticals, Inc. at UBS Global Life Sciences Conference (Live)
09/20/10 at 7:30 a.m. ET |
|
|
|
| Date | Title | | | 12/26/07 | Dr. Robert Karr Resigns from Management Position at Idera| Remains as Consultant and Member of Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 26, 2007--Idera
Pharmaceuticals (Nasdaq: IDRA) today announced Robert W. Karr, M.D.,
President, has resigned from his full-time management position at the
Company effective December 31st, 2007. He will remain a member of the
Company's Board of Directors and has entered into a consulting
agreement with the Company.
"It's been my pleasure to work with Bob over the last two years.
Ever... |
|  | | 12/19/07 | Idera Pharmaceuticals and Merck KGaA to Collaborate on Development of TLR9 Agonists for Treatment of Cancer| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 19, 2007--Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) announced today that it has
entered into a worldwide licensing and collaboration agreement with
Merck KGaA of Darmstadt, Germany, for the research, development and
commercialization of Idera's Toll-like Receptor 9 (TLR9) agonists for
the treatment of cancer.
Under the agreement, Idera has agreed to exclusively license the
therapeutic oncology applications, excluding cancer vaccines, of its... |
| | | 12/13/07 | Idera Pharmaceuticals Initiates Phase 1b Trial of IMO-2055 in Combination with Targeted Agents in Non-Small Cell Lung Cancer| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 13, 2007--Idera
Pharmaceuticals (Nasdaq: IDRA) today announced that the first patient
has been dosed in a Phase 1b trial evaluating IMO-2055 in combination
with Tarceva(R) and Avastin(R) in patients with non-small cell lung
cancer (NSCLC). IMO-2055 is a novel agonist of Toll-like Receptor
(TLR) 9. Tarceva and Avastin are targeted agents approved by the U.S.
Food and Drug Administration for the treatment of NSCLC.
"Initiation of this Phase 1b... |
| | | 12/10/07 | Idera Pharmaceuticals Common Stock Begins Trading on NASDAQ Global Market Today|
Cambridge, MA, December 10, 2007 – Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that its common stock will commence trading on the NASDAQ Global Market effective with the opening of the market today under the new ticker symbol “IDRA”. Idera previously announced that it received approval from The NASDAQ Stock Market® for the listing of its common stock and that it intended to transfer its listing from the American Stock Exchange to the NASDAQ.
About NASDAQ
NASDAQ is the la... |
| | | 11/26/07 | Idera Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 26, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced that it has received
notification from The NASDAQ Stock Market(R) that its common stock has
been approved for listing on NASDAQ Global Market. The Company is
currently going through all the required regulatory processes
associated with the transition and expects its common stock to begin
trading on NASDAQ under its new symbol IDRA on Monday, December 10,
2007. The Company's common... |
| | | 11/20/07 | Idera Pharmaceuticals to Present at Upcoming Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 20, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced that management will
discuss the Company's Toll-Like Receptor - targeted drug discovery and
development programs and provide a general corporate overview at the
following conferences:
Lazard Capital Markets 4th Annual Healthcare Conference, on
Tuesday, November 27, 2007, at 9:30 a.m. (EST) at The New York
Palace Hotel in New York City.
BMO Capital Ma... |
| | | 11/14/07 | Idera Pharmaceuticals Appoints Louis Arcudi as Chief Financial Officer| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 14, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP), a biopharmaceutical company focused
on developing therapeutics targeting Toll-like Receptors (TLR),
announced today the appointment of Louis J. Arcudi III, as Chief
Financial Officer. Over the past 10 years, Mr. Arcudi has served in
various finance and administration capacities at Peptimmune, Inc.,
Genzyme Molecular Oncology Corporation and Genzyme Corporation. Mr.
Arcudi will join the Company o... |
| | | 11/13/07 | Idera Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2007| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 13, 2007--Idera
Pharmaceuticals (AMEX: IDP) today reported financial results for the
three and nine months ended September 30, 2007.
"Idera expanded its scientific leadership in Toll-like Receptor
(TLR) research during the third quarter. We reported encouraging
preclinical findings with TLR agonists and antagonists, prepared to
initiate combination studies with IMO-2055 in oncology, and initiated
a phase 1 trial evaluating IMO-2125, our seco... |
| | | 11/09/07 | Idera Pharmaceuticals Announces Publication of Study Evaluating Synthetic Toll-like Receptor 9 Agonists| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 9, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced the publication of
data from a preclinical study evaluating oligonucleotide-based
compounds containing novel synthetic immune stimulatory motifs that
act as agonists of Toll-like Receptor (TLR) 9. These results offer
insight into specific chemical modifications of TLR9 agonists and
their ability to stimulate immune responses. The paper entitled
"Agonists of Toll-like Receptor 9 Con... |
| | | 10/05/07 | Idera Pharmaceuticals to Participate at BIO InvestorForum 2007| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 5, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert Karr,
M.D., President of Idera, will discuss the Company's Toll-Like
Receptor - targeted drug discovery and development programs and
provide a general corporate overview at the BIO InvestorForum 2007
taking place October 9-11, 2007, at the Palace Hotel in San Francisco,
CA. The presentation will begin at 10:30 a.m. PDT (1:30 p.m. EDT) on
Thursday, October 11. The corpor... |
| | | 10/03/07 | Idera Pharmaceuticals Announces Issuance of US Patent for Novel Oligonucleotide Compositions Targeted to Toll-like Receptors| CAMBRIDGE, Mass., Oct 03, 2007 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced the
issuance of US patent 7,276,489 (the '489 patent) for novel
oligonucleotide compositions. The claims of this patent, entitled
"Modulation of Immunostimulatory Properties of Oligonucleotide-Based
Compounds By Optimal Presentation of 5' Ends," cover oligonucleotide
compositions in which two oligonucleotides are attached together
through their 3' ends and contain various synthetic imm... |
| | | 09/27/07 | Idera Pharmaceuticals Announces the Appointment of Hans Mueller, Ph.D., to Its Board of Directors| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 27, 2007--Idera
Pharmaceuticals, Inc. (Amex: IDP) today announced the election of Hans
Mueller, Ph.D., to the Company's Board of Directors. Dr. Mueller was
elected as a class I director for a term expiring at the Company's
annual meeting in 2008.
Dr. Mueller most recently served as Senior Vice President of
Global Business Development at Wyeth Pharmaceuticals, where he played
a key role in leading world-wide licensing, partnerships,
colla... |
| | | 09/17/07 | Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 17, 2007--Idera
Pharmaceuticals (AMEX: IDP) today announced that the first patient has
been dosed in a Phase 1 trial evaluating IMO-2125 for the treatment of
patients with hepatitis C virus (HCV) infection. IMO-2125 is a novel
agonist of Toll-like Receptor (TLR) 9.
"IMO-2125 is a TLR9 agonist that Idera designed to induce
endogenous interferon-alpha along with other immune response factors
to treat hepatitis C," said Sudhir Agrawal, D. Ph... |
| | | 09/17/07 | Idera Pharmaceuticals Presents Preclinical Data on IMO-2125 and Other TLR9 Agonists| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 17, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP), today announced preclinical data on
IMO-2125, its lead Toll-Like Receptor (TLR) 9 agonist for the
treatment of hepatitis C virus (HCV) infection, and other TLR9
agonists. The data were presented at the 47th Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC) being held in
Chicago, IL, September 17-20, 2007.
Abstract 1583 entitled "IMO-2125, a TLR9 Agonist that Induces... |
| | | 09/13/07 | Idera Pharmaceuticals to Participate in Upcoming Conferences| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 13, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert Karr,
M.D., President of Idera, will discuss the Company's Toll-Like
Receptor - targeted drug discovery and development programs at the
following conferences:
-- The 4th Annual Merriman Curhan Ford & Co. Investor Summit on
Monday, September 17, 2007, during the Toll-Like Receptor Drug
Development Panel beginning at 1:15 p.m. PDT at the Mar... |
| | | 09/06/07 | Idera Pharmaceuticals Presents Interim Data from Phase 1 Study Evaluating IMO-2055 in Combination with Gemcitabine and Carboplatin| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 6, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP), today announced interim results
from a Phase 1 clinical trial being conducted by the Company
evaluating IMO-2055, the Company's lead Toll-Like Receptor (TLR) 9
agonist, in combination with gemcitabine and carboplatin in patients
with advanced solid tumors. The data were presented in a poster
entitled "Initial phase 1 results of gemcitabine, carboplatin and
IMO-2055, a toll-like receptor agonist,... |
| | | 08/29/07 | Idera Pharmaceuticals Announces Issuance of US Patent for Novel Immunostimulatory Oligonucleotide Compositions| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 29, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced the issuance of US
patent 7,262,286 (the '286 patent) for novel immunostimulatory
oligonucleotide compositions. The claims of this patent, entitled
"Modulation of Immunostimulatory Activity of Immunostimulatory
Oligonucleotide Analogs By Positional Chemical Changes" cover
oligonucleotide compounds comprising a synthetic immunostimulatory
dinucleotide motif. The claimed dinucleotid... |
| | | 08/14/07 | Idera Pharmaceuticals Announces Publication of Preclinical Data on Toll-Like Receptor 7 and 8 Agonists| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 14, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced the publication of
preclinical data on its stabilized immune modulatory RNA (SIMRA)
compounds that act as agonists of Toll-Like Receptors (TLR) 7 and 8.
In this publication, data were reported from preclinical studies in
human cell-based assays and in vivo in non-human primates in which
SIMRA compounds induced immune responses. In the reported data the
agonistic activity for TLR 7... |
| | | 08/03/07 | Idera Pharmaceuticals to Present at Canaccord Adams 27th Annual Global Growth Conference| CAMBRIDGE, Mass., Aug 03, 2007 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced that
Robert Karr, M.D., President of Idera, will discuss the Company's
Toll-Like Receptor - targeted drug discovery and development programs
and provide a general corporate overview at the Canaccord Adams 27th
Annual Global Growth Conference taking place August 7-9, 2007, in
Boston, MA. The presentation will begin at 2:30 p.m. EDT on Wednesday,
August 8, 2007.
The presentation will be... |
| | | 08/01/07 | Idera Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2007| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 1, 2007--Idera
Pharmaceuticals (AMEX: IDP) today reported financial results for the
three and six months ended June 30, 2007.
"Our financial results for the second quarter reflect continued
execution of our business strategy to advance our development programs
with our lead candidates, IMO-2055 and IMO-2125, to evaluate novel
Toll-Like Receptor (TLR) antagonists and TLR7, 8 and 9 agonists in
preclinical models, and to support our collabora... |
| | | 07/17/07 | Idera Pharmaceuticals Announces Publication of Study of Toll-Like Receptor 9 Agonist in Combination with Avastin(R) in Preclinical Colon Cancer Model| CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 17, 2007--Idera
Pharmaceuticals (AMEX: IDP) today announced the publication of
preclinical data demonstrating that its Toll-like Receptor (TLR) 9
agonist in combination with bevacizumab, the anti-vascular endothelial
growth factor (VEGF) monoclonal antibody, resulted in co-operative
anti-tumor activity in animal models of colon cancer. Bevacizumab is
marketed as Avastin(R). The paper entitled "Novel TLR9 agonist
synergizes by different mechanism... |
| | | 07/17/07 | Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Rheumatoid Arthritis Models| CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 17, 2007--Idera
Pharmaceuticals, Inc. (AMEX: IDP) today announced the presentation of
preclinical data using its proprietary antagonists of Toll-like
receptors (TLR) 7 and 9 in mouse models of collagen-induced arthritis
(CIA), a commonly used model for rheumatoid arthritis (RA). RA is an
autoimmune disease characterized primarily by Th1-like immune
responses. The presentation entitled "A Novel Class of DNA-Based TLR
Antagonists Ameliorates Colla... |
| | | 05/21/07 | Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007|
Click here to access PDF press release.... |
| | | 05/15/07 | Idera Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2007| Click here to access PDF press release.
... |
| | | 05/10/07 | Idera Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference| Click here to access PDF press release.... |
| | | 05/03/07 | Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Toll-Like Receptor Panel at BIO 2007| Click here to access PDF press release.... |
| | | 04/18/07 | Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR| Click here to access PDF press release.... |
| | | 04/05/07 | Idera Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference| Click here to access PDF press release.... |
| | | 03/06/07 | Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results| Click here to access PDF press release.... |
| | | 03/06/07 | Idera Pharmaceuticals Announces Extension of Research Collaboration on Asthma and Allergy| Click here to access PDF press release.... |
| | | 03/06/07 | Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2006 Financial Results| Click here to access PDF press release.... |
| | | 02/21/07 | Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development| Click here to access PDF press release.... |
| | | 02/14/07 | Idera Pharmaceuticals Announces Issuance of US Patent for Oligonucleotide Compositions that Activate Toll-Like Receptors| Click here to access PDF press release.... |
| | | 02/12/07 | Idera Pharmaceuticals Presents Preclinical Data in Lupus Disease Models on Use of Novel Class of Antagonists for Toll-Like Receptors| Click here to access PDF press release.... |
| | | 02/05/07 | Idera Pharmaceuticals to Present at Upcoming Conferences| Click here to access PDF press release.... |
| |
|
|
| |
